NEUROAID OFFERS HOPE FOR RECOVERY

There is a clear lack of medicine to respond to the needs of stroke survivors during their rehabilitation process. After over 100 clinical trials failed, many western clinicians are looking at Traditional Medicines as a source of new treatments. Last April, a review article in the "Stroke" journal pointed out the potential of a number of safe Traditional Chinese Medicine.

Moleac is a biopharmaceutical company, founded by a group of esteemed scientists including a Nobel laureate. Moleac has identified NeuroAid to help stroke patients to achieve fuller recovery.

NeuroAid was initially developed in China as a Traditional Chinese Medicine for stroke patients rehabilitation. Unlike most treatments coming from China, NeuroAid has undergone high quality clinical trials showing effectiveness and safety and is manufactured with stringent quality control. It was introduced in 2001 and is now reaching about 200,000 patients every year in Asia.

A study on 605 patients, enrolled between 2 weeks and 6 months after their stroke, has shown that patients receiving NeuroAid have more than twice as many chances to reach independence after the first month of the 3 months long recommended protocol. Specifically on neurological deficits, NeuroAid has shown strong impact on limbs, toes, fingers, facial paralysis reduction. According to the medical experience developed in China, NeuroAid is also relevant for patient who want to enhance their rehabilitation program even after six month of the stroke event.

In addition, recent clinical trials have shown that NeuroAid does not significantly modify hematological, hemostatic, and biochemical parameters in normal subjects and stroke patients. NeuroAid is safe and has very few reported side effects, which have been found to be of minor concern (such as nausea, vomiting or increased thirst).

Moleac has developed NeuroAid with the support of a renowned mainstream medicine practice clinical team. In addition to prove efficacy, all efforts have been focused to ensure the quality and safety of NeuroAid: modern evaluation practices, such as Good Manufacturing Practice compliance, quality testing, heavy metal dosage and microbial tests have been implemented Every batch of NeuroAid is analyzed thoroughly by third party laboratories to confirm compliance with international standards, and safety for patients.

Moleac, who is also a member of the American Herbal Products Association, is now bringing NeuroAid to patients internationally.

NeuroAid has shown efficacy for patients who suffered a stroke in the past 6 months and have resulting loss of motor function or independence. According to medical experience, NeuroAid can also be relevant to patient who had their stroke for a longer period of time.

As of today NeuroAid is marketed by Moleac in several countries as well as on its dedicated website www.NeuroAid.com. The NeuroAid protocol consists of 3 capsules to be taken 4 times a day over a three-month period. Moleac expects to launch NeuroAid10 on the US market by the end of the year.

Strong interest from the international medical community is now driving several additional clinical trials on NeuroAid. For example, CHIMES study is evaluating the efficacy of NeuroAid at the early stage of stroke onset on 1100 stroke patients in Asia. Moleac plans to use the result of these clinical trials to establish the benefits of NeuroAid to the health insurers and gain reimbursement of NeuroAid for patients. To support this academic research please log on to www.chimes-society.org.

NeuroAid can be ordered on www.neuroaid.com and is delivered worldwide. For more information, clinical teams or patients are invited to logon to www.neuroaid.com / www.moleac.net or e-mail info@neuroaid.com for a quick and personalized response. You are also welcome to call our toll-free number at 1-800-882-4046.